Safety Profile
Known Safety Concerns
- Stimulating effect may cause insomnia or irritability at high doses
- Possible interaction with antidepressants (MAOIs, SSRIs)
- May lower blood pressure and blood sugar
- Avoid in bipolar disorder -- may trigger manic episodes
Contraindications
- Stimulating effect may cause insomnia or irritability at high doses
- Possible interaction with antidepressants (MAOIs, SSRIs)
Interactions
Information not yet available for this ingredient profile.
Evidence and Scientific Findings
Ingredient Overview
Rhodiola rosea is an adaptogenic herb used for stress, fatigue, and cognitive performance. Clinical trials support modest benefits for stress-related fatigue. It is generally well tolerated. Stimulating effects may cause insomnia or agitation in some individuals. It may interact with antidepressants via monoamine pathways.
Biological and Chemical Classification
- Scientific Name
- Rhodiola rosea
Mechanism of Action
Information not yet available for this ingredient profile.
Clinical Evidence of Effectiveness
Information not yet available for this ingredient profile.
Pharmacokinetics
Information not yet available for this ingredient profile.
Recommended Dosage
Information not yet available for this ingredient profile.
SETI — Scientific Evidence Transparency Index
Executive Summary — Ingredient Assessment
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or RCT)
- Main clinical benefit observed: Botanical
- Evidence consistency: High consistency across studies (100%)
- Stimulating effect may cause insomnia or irritability at high doses
- Possible interaction with antidepressants (MAOIs, SSRIs)
- May lower blood pressure and blood sugar
- Avoid in bipolar disorder -- may trigger manic episodes
The available scientific evidence for Rhodiola Rosea indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.
Total SETI Score
High risk| Evidence quality | 10/40 |
| Evidence consistency | 20/20 |
| Safety signals | 0/20 |
| Study recency | 10/10 |
| Evidence transparency | 10/10 |
Evidence Summary
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or systematic review)
- 0 studies identified benefits or no safety concern (GREEN)
- 10 studies reported limited or advisory safety evidence (YELLOW)
Evidence Policy
Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.
Last updated: 25 აპრ 2026, 02:43
Evidence Distribution
-
Observational / other LOW evidence YELLOWNatural senolytic activity of Rhodiola rosea extract alleviates age-associated phenotypes via paraptosis. ↗Furuuchi R et al.. Natural senolytic activity of Rhodiola rosea extract alleviates age-associated phenotypes via paraptosis.. iScience. 2026. PMID:42028013.PMID 42028013 ↗Journal iScienceYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/42028013/
-
Observational / other LOW evidence YELLOWSalidroside in heavy metal toxicity: a mechanistic review of antioxidant, anti-inflammatory, and anti-apoptotic pathways. ↗Sun W et al.. Salidroside in heavy metal toxicity: a mechanistic review of antioxidant, anti-inflammatory, and anti-apoptotic pathways.. Biometals. 2026. PMID:42018209.PMID 42018209 ↗Journal BiometalsYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/42018209/
-
Observational / other LOW evidence YELLOWBiosynthesis of active small molecule prenylsalidroside a and its anti-inflammatory activity. ↗Xue JH et al.. Biosynthesis of active small molecule prenylsalidroside a and its anti-inflammatory activity.. Nat Prod Res. 2026. PMID:42008007.PMID 42008007 ↗Journal Nat Prod ResYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/42008007/
-
Observational / other LOW evidence YELLOWAdaptive Laboratory Evolution for Enhanced Tyrosol Tolerance Enables High-Titer Salidroside Production in Escherichia coli. ↗Li C et al.. Adaptive Laboratory Evolution for Enhanced Tyrosol Tolerance Enables High-Titer Salidroside Production in Escherichia coli.. ACS Synth Biol. 2026. PMID:41979105.PMID 41979105 ↗Journal ACS Synth BiolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41979105/
-
Observational / other LOW evidence YELLOWSalidroside ameliorates skin aging in male mice by promoting collagen regeneration via modulation of FOS and MMP9. ↗Wang Z et al.. Salidroside ameliorates skin aging in male mice by promoting collagen regeneration via modulation of FOS and MMP9.. Biogerontology. 2026. PMID:41961336.PMID 41961336 ↗Journal BiogerontologyYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41961336/
-
Observational / other LOW evidence YELLOWSalidroside Ameliorates Polycystic Ovary Syndrome in Mice by Regulating the AKT/NF-u03baB/NLRP3-HAS2 Axis. ↗Li JH et al.. Salidroside Ameliorates Polycystic Ovary Syndrome in Mice by Regulating the AKT/NF-u03baB/NLRP3-HAS2 Axis.. Food Sci Nutr. 2026. PMID:41948383.PMID 41948383 ↗Journal Food Sci NutrYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41948383/
-
Observational / other LOW evidence YELLOWA Rhodiola-derived acidic glycopeptide maintains sleep homeostasis by regulating brain lipid metabolism in Drosophila. ↗Xu R et al.. A Rhodiola-derived acidic glycopeptide maintains sleep homeostasis by regulating brain lipid metabolism in Drosophila.. Phytomedicine. 2026. PMID:41931999.PMID 41931999 ↗Journal PhytomedicineYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41931999/
-
Observational / other LOW evidence YELLOWPhenolic Compounds and Elemental Composition of Rhodiola rosea (Crassulaceae) from Altai Mountains. ↗Zibareva LN et al.. Phenolic Compounds and Elemental Composition of Rhodiola rosea (Crassulaceae) from Altai Mountains.. Dokl Biol Sci. 2026. PMID:41912825.PMID 41912825 ↗Journal Dokl Biol SciYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41912825/
-
Observational / other LOW evidence YELLOWRhodiola rosea, Ginkgo biloba, and Ashwagandha as novel antidepressant supplements: converging monoaminergic, neurotrophic, anti-inflammatory, and brain health pathways in depressive disorders. ↗Li X et al.. Rhodiola rosea, Ginkgo biloba, and Ashwagandha as novel antidepressant supplements: converging monoaminergic, neurotrophic, anti-inflammatory, and brain health pathways in depressive disorders.. Front Nutr. 2026. PMID:41909050.PMID 41909050 ↗Journal Front NutrYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41909050/
-
Observational / other LOW evidence YELLOWClinical evidence for the adaptogenic effects of Withania somnifera and Rhodiola rosea - Au00a0systematic review with molecular interpretation of psychometric outcomes. ↗u0141uszczak J et al.. Clinical evidence for the adaptogenic effects of Withania somnifera and Rhodiola rosea - Au00a0systematic review with molecular interpretation of psychometric outcomes.. Ann Agric Environ Med. 2026. PMID:41906501.PMID 41906501 ↗Journal Ann Agric Environ MedYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41906501/
Score Transparency
0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.
Method: Q = number of approved references ÷ 10 (capped at 1.0)
Limited — mostly case reports or animal studies
Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.
Mixed or neutral — roughly equal benefit and risk signals
Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.
One or more monitoring-level safety signals active
Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.
Final GIRI Score for Rhodiola Rosea. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
Full methodology & data sources
The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.
- References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
- Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
- Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
- Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
Risk Level Classification
Based on available regulatory signals and scientific evidence, this ingredient presents a low safety concern under normal conditions of use.
0–3.0
3.0–5.5
5.5–7.5
7.5–10
The score pin shows exactly where this ingredient falls on the fixed risk scale.
What drove the Low classification for Rhodiola Rosea
A score of 3.0 places this ingredient in the Low band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
0 approved references.
Limited — mostly case reports or animal studies (Level 4–5).
Neutral or mixed — benefit and risk signals roughly balanced.
No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.
No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).
How are the Low / Moderate / High / Critical thresholds defined?
The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:
| Level | Score | Meaning |
|---|---|---|
| LOW | 0.0 – 2.9 | Sparse or predominantly beneficial evidence. No active safety alerts. |
| MODERATE | 3.0 – 5.4 | Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups. |
| HIGH | 5.5 – 7.4 | Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended. |
| CRITICAL | 7.5 – 10 | Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision. |
Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.